XTL Biopharmaceuticals Ltd. - American Depositary Shares (XTLB) closed at $1.62 on November 17, 2026, up 5.2% from the previous close, on volume of 1,938 shares (30-day average 7,984).
Data as of November 17, 2026.
No press releases found.
Market Chameleon (Wed, 29-Apr 5:53 AM ET)
Market Chameleon (Wed, 29-Apr 5:34 AM ET)
Market Chameleon (Tue, 13-Jan 5:29 AM ET)
XTL Biopharmaceuticals Ltd is an intellectual property-based company focused on the development, management, and commercialization of intellectual property. The Company is engaged in biotechnology through its subsidiary Psyga Bio and in the biopharmaceutical industry with hCDR1, a novel compound working via a novel mechanism of action for the treatment of Systemic Lupus Erythematosus (SLE) and a potential treatment for Sjogren's syndrome (SS). It focuses on the acquisition and development of proprietary products and late-stage pharmaceutical product candidates for the treatment of unmet clinical needs.
XTL Biopharmaceuticals Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol XTLB.
As of November 17, 2026, XTLB stock price climbed to $1.62 with 1,938 million shares trading.
XTLB has a market cap of $3.98 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, XTLB traded as high as $19.96 and as low as $1.52.
XTLB has underperformed the market in the last year with a price return of -56.0% while the SPY ETF gained +10.1%. XTLB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -41.8% and -4.7%, respectively, while the SPY returned -5.4% and -2.6%, respectively.
XTLB support price is $1.36 and resistance is $1.72 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XTLB shares will trade within this expected range on the day.